IP Library Granted Patent US 8,921,524
Granted Patent B2
US 8,921,524 · App. 12/645,684 · Granted Dec 30, 2014

Binding molecules

Inventors: Franklin Geradus Grosveld (Rotterdam, NL); Richard Willhelm Janssens (Rotterdam, NL); Dubravka Drabek (Rotterdam, NL); Roger Kingdon Craig (Sandbach, GB)
Assignee: Erasmus University Medical Centre
C07K16/241C07K16/00C07K16/1054C07K16/1063C07K16/1232C07K2317/22C07K2317/31C07K2317/53C07K2317/569C07K2319/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,921,524
App. No.
12/645,684
Granted
Dec 30, 2014
Kind
B2
Abstract

The present invention relates to the manufacture of a diverse repertoire of functional heavy chain-only antibodies that undergo affinity maturation, and uses thereof. The invention also relates to the manufacture and use of a diverse repertoire of class-specific heavy chain-only antibodies and to the manufacture and use of multivalent polypeptide complexes with antibody heavy chain functionality, preferably antibody heavy chain binding functionality, constant region effector activity and, optionally, additional effector functions. The present invention also relates to a method of generation of fully functional heavy chain-only antibodies in transgenic mice in response to antigen challenge. In particular, the present invention relates to a method for the generation of human antigen-specific, high affinity, heavy chain-only antibodies of any class, or mixture of classes and the isolation and expression of fully functional VH antigen-binding domains.

Claims (22)

1. A method for the production of soluble, antigen-specific heavy chain only antibodies comprising:

(a) immunising a transgenic mouse expressing a heterologous V H heavy chain locus with an antigen wherein:

(i) the V H heavy chain locus comprises a variable region comprising at least one naturally occurring human V H gene segment, at least one D gene segment, at least one J gene segment and at least one heavy chain constant region;

(ii) each constant region does not encode a functional C H 1 domain;

(iii) the V H gene segment, D gene segment and J gene segment are capable of recombining to form a VDJ coding sequence;

(iv) the recombined V H heavy chain locus, when expressed upon antigen challenge, is capable of forming a soluble, heavy chain-only antibody comprising a soluble, antigen-specific V H binding domain and a constant effector region devoid of a functional C H 1 domain with an antigen;

(b) cloning a soluble heavy chain only antibody resulting from recombination between single V H , D and J gene segments and encoding a soluble, antigen-specific V H binding domain from an antibody-producing cell of said immunised transgenic mouse after affinity maturation via somatic mutation; and

(c) producing said soluble, antigen specific heavy chain only antibody, or a soluble antigen-specific binding domain derived therefrom, from the clone of step (b).

2. The method of claim 1 , wherein steps (b) to (c) of claim 1 are carried out by:

(a) (isolating a cell or tissue expressing an antigen-specific, soluble heavy chain-only antibody of interest;

(b) producing a hybridoma from the cell or tissue of step (a);

(c) cloning the heavy chain-only antibody mRNA from said hybridoma; and

(d) producing said soluble, antigen-specific heavy chain only antibody by isolating and expressing mRNA encoding said soluble, antigen-specific heavy chain only antibody from the mRNA of step (c).

3. The method of claim 1 , wherein steps (b) to (c) of claim 1 are carried out by:

(a) isolating a cell or tissue expressing an antigen-specific, soluble heavy chain-only antibody of interest;

(b) cloning the V H locus from mRNA derived from the isolated cell or tissue;

(c) displaying the encoded VH domain using phage or similar library;

(d) identifying soluble, antigen-specific V H domain(s);

(e) cloning the V H locus into an expression vector comprising an immunoglobulin heavy chain effector region of choice; and

(f) expressing the soluble, antigen-specific heavy chain only antibody.

4. The method of claim 1 , wherein the soluble heavy chain only antibody locus comprises naturally occurring human D and J gene segments.

5. The method of claim 1 , wherein the heavy chain only antibody locus comprises more than one V H gene segment, more than one D gene segment and more than one J gene segment.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 9, 2023
From: ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM
To: HARBOUR ANTIBODIES B.V.
Reel/Frame 065157/0018 →
CORRECTIVE ASSIGNMENT TO CORRECT THE RECORDATION COVER SHEET THAT THE DOCUMENT ALSO SERVES AS AN OATH/DECLARATION PREVIOUSLY RECORDED ON REEL 033745 FRAME 0861. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT OF ASSIGNORS INTEREST. Recorded Mar 10, 2015
From: GROSVELD, FRANKLIN GERARDUS; JANSSENS, RICHARD WILHELM; DRABEK, DUBRAVKA
To: ERASMUS UNIVERSITY MEDICAL CENTRE
Reel/Frame 035167/0332 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 16, 2014
From: GROSVELD, FRANKLIN GERARDUS; JANSSENS, RICHARD WILHELM; DRABEK, DUBRAVKA
To: ERASMUS UNIVERSITY MEDICAL CENTRE
Reel/Frame 033745/0861 →
Priority Claims (2)
GB 0416392.9 · Jul 22, 2004 · national
GB 0511881.5 · Jun 10, 2005 · national
Continuity (2)
Continuation 11658361
Related Publication 20100197897A1 · Aug 5, 2010